• Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Journal Of Epileptology
  • Acta Neurobiologiae Experimentalis


Review Paper | 10-December-2015

Antiepileptic drugs as a new therapeutic concept for the prevention of cognitive impairment and Alzheimer’s disease. Recent advances

Introduction. Excessive accumulation of amyloid-beta (A_) peptides in the brain results initially in mild cognitive impairment (MCI) and finally in Alzheimer’s disease (AD). Evidences from experimental and clinical studies show that pathological hyperexcitability of hippocampal neurons is a very early functional impairment observed in progressive memory dysfunctions. Therefore, antiepileptic drugs (AEDs) whose mechanism of action is aimed at inhibition of such neuronal hyperexcitability

Krzysztof Sendrowski, Wojciech Sobaniec

Journal of Epileptology, Volume 23 , ISSUE 2, 139–147

Review Paper | 26-March-2014

Selected classical and novel antiepileptic drugs – mechanisms of action, neuroprotection, and effectiveness in epileptic and non-epileptic conditions

Introduction. One of the most common neurological disorders is epilepsy, characterised by recurrent spontaneus seizures. Although not fully efficient in ca 30% of patients, pharmacologic treatment of epilepsy plays an important therapeutic approach not only against epilepsy. Aim. To provide data on the mechanism of action, activity and neuroprotective efficacy in experimental conditions, clinical efficacy against epilepsy and non-epileptic diseases of major, classical and newer antiepileptic

Magdalena Chrościńska-Krawczyk, Magdalena Wałek, Bożydar Tylus, Stanisław J. Czuczwar

Journal of Epileptology, Volume 22 , ISSUE 1, 37–50

review-article | 02-July-2019

Rational polytherapy: Myth or reality?

antiepileptic drugs (AEDs) was based on the avoidance of combined pharmacodynamic or pharmacokinetic side effects (French and Faught, 2009). In the ninth decade of the twentieth century, the so-called second-generation antiepileptic drugs (SGAEDs) started being commercialized. They had the advantages of better pharmacokinetic and pharmacodynamic profiles, less side effects and fewer drug interactions when compared with their first generation counterparts. Furthermore, several of them had novel mechanisms of

José Pimentel, José Manuel Lopes Lima

Journal of Epileptology, Volume 27 , 27–34

research-paper | 12-August-2019

Coumarins as potential supportive medication for the treatment of epilepsy

effect of coumarins on the central nervous system (CNS). Therefore, numerous experimental studies focus on disorders such as epilepsy, schizophrenia, depressive and anxiety disorders or Alzheimer’s disease (Skalicka-Woźniak et al., 2016). Possible anticonvulsant properties of natural coumarins Epileptic seizures are the result of excessive abnormal neuronal activity in the brain. The primary treatment for epilepsy is the administration of antiepileptic drugs (AEDs). These drugs reduce the frequency

Jarosław Bryda, Mirosław Zagaja, Aleksandra Szewczyk, Marta Andres-Mach

Acta Neurobiologiae Experimentalis, Volume 79 , ISSUE 2, 126–132

Hypothesis | 30-August-2017

Do minocycline and other suppressors of microglia reactivity have a future in prevention or treatment of epilepsy?

different animal models of epilepsy as well as in clinical study in patients. The most promising compound seems to be minocycline which in some studies has been shown to possess antiepileptogenetic action. On the other hand, some antiepileptic drugs exhibit marked anti-inflammatory potency. Conclusions. There are much data to suggest that there is significant opportunity for designing new antiepileptic drugs whose primary mechanism of action entails the inhibition of neuroinflammatory processes.

Władysław Lasoń, Joanna Ślusarczyk, Magdalena Regulska, Monika Leśkiewicz, Agnieszka Basta-Kaim

Journal of Epileptology, Volume 25 , ISSUE 1-2, 9–20

research-article | 18-December-2018

Determinants of medication withdrawal strategy in the epilepsy monitoring unit*

(Cox et al., 2017). Monitoring can be used in patients with infrequent events, and tapering antiepileptic drugs (AEDs) has a beneficial effect on seizure frequency in this population (Al Kasab et al., 2016). There is little consensus regarding the best AED withdrawal regimen during VEEG. A recent survey of epilepsy monitoring units (EMUs) revealed 80% of centers do not have a protocol for medication taper, and withdrawal is generally done on a case by case basis (Buelow et al., 2009). Guld et al

Alendia Hartshorn, Yasser Shahrour, Angeline S. Andrew, Krzysztof Bujarski

Journal of Epileptology, Volume 26 , ISSUE 1-2, 15–19

Review Paper | 18-December-2014

Failure of a first regimen of monotherapy to control the newly diagnosed epilepsies. What to do next?

José Pimentel

Journal of Epileptology, Volume 22 , ISSUE 2, 109–112

Review Paper | 06-April-2016

Anticonvulsant therapy in brain-tumor related epilepsy

Walter Fröscher, Timo Kirschstein, Johannes Rösche

Journal of Epileptology, Volume 24 , ISSUE 1, 41–56

research-article | 27-March-2019

Recommendations of the Polish Society of Epileptology for the treatment of epileptic seizure in adult patients in Poland: an update

Joanna Jędrzejczak, Beata Majkowska-Zwolińska, Danuta Ryglewicz, Ewa Nagańska, Maria Mazurkiewicz-Bełdzińska

Journal of Epileptology, Volume 27 , 9–16

case-report | 30-November-2019

Pharmacoresistant epilepsy associated with mutations in the KCNB1 and RELN genes. A case report

INTRODUCTION Epilepsy is one of the most common neurological diseases worldwide and is considered a major public health problem, with socioeconomic problems (Camfield and Camfield, 2015; López González et al., 2015). Generally, this disease can be successfully treated in most cases. However, there is a high percent of patients that does not respond favorably to common antiepileptic drugs (AED) despite the continued development of new AED the last two decades, resulting in pharmacoresistance

Adamantios Katerelos, Nikolaos Zagkos, Dimitra Alexopoulou, Stella Mouskou, Anastasia Korona, Emmanouil Manolakos

Journal of Epileptology, Volume 28 , 57–61

Case report | 15-June-2016

Concomitant treatment with imipenem causes a rapid and extensive decrease in the plasma concentrations of valproic acid

Background. Valproic acid (VPA) is a wide-spectrum antiepileptic drug used both in children and in adults. We describe a clinically important interaction between VPA and imipenem, a carbapenem antimicrobial. Case presentation. Our patient was a 19-year-old man with childhood onset of mental retardation and severe epilepsy. He was hospitalized due to pneumonia. His antiepileptic drugs, including VPA, were administered intravenously. Due to pneumonia, intravenously administered imipenem was

Tapani Keränen, Hanna Kuusisto

Journal of Epileptology, Volume 24 , ISSUE 1, 63–66

Case report | 31-March-2016

Successful treatment of epilepsia partialis continua due to Rassmussen encephalitis with perampanel

Background. Epilepsia partialis continua (EPC) is a difficult to treat condition, which tends to be refractory to antiepileptic drugs (AEDs). We previously published two other treatment episodes of EPC due to stroke and vascular dementia with a possible effect of perampanel (PER). Aim. With the publication of a third treatment episode of EPC terminated by the administration of PER we would like to suggest that PER may be an effective treatment option in this condition. Material and Methods. We

Katja Göde, Annette Grossmann, Johannes Rösche

Journal of Epileptology, Volume 24 , ISSUE 1, 67–70

Case report | 14-November-2014

Ictal Forced Repetitive Swearing in Frontal Lobe Epilepsy: Case report and review of the literature

Introduction. Dominant presentation of ictal forced repetitive swearing has been rarely addressed and could be misdiagnosed. Case report. We report a 45-year-old man with a long history of right frontal lobe epilepsy (FLE) who developed forced repetitive swearing during hypermotor seizures. His seizures were refractory to different antiepileptic drugs (AEDs). Scalp video-EEG telemetry suggested a right frontal epileptic focus. Magnetic resonance imaging (MRI) suggested focal cortical dysplasia

Marjan Dolatshahi, Alexei Yankovsky

Journal of Epileptology, Volume 22 , ISSUE 2, 113–119

Review Paper | 07-June-2016

Depression and anxiety in people with epilepsy: Why should we identify?

validity of simple screening tools for the detection of depression and anxiety. Review. Approximately one quarter of PWE have been known to be suffered from depression. The frequency of depression and anxiety was closely related to poor seizure control. Depression and anxiety have been reported to have a bidirectional relationship with epilepsy. The higher degree of depression and anxiety was more likely to elicit the suicidal ideation and attempt, adverse events and poor compliance of antiepileptic

Sung-Pa Park

Journal of Epileptology, Volume 24 , ISSUE 1, 57–62

review-article | 23-March-2019

Pharmacological and non-pharmacological approaches to life threatening conditions in epilepsy

Barbara Błaszczyk, Aleksandra Walczak, Natalia Ścirka, Agnieszka Konarzewska, Barbara Miziak, Stanisław J. Czuczwar

Journal of Epileptology, Volume 28 , 15–26

Original Paper | 22-December-2016

Additive interactions between retigabine and oxcarbazepine in the chimney test and the model of generalized tonic-clonic seizures in mice

Introduction. Patients with pharmacoresistant epilepsy are usually treated with two or more antiepileptic drugs (AEDs). The search for therapeutically efficacious AED combinations is still a challenging issue for clinicians and epileptologists throughout the world. Aim. To determine the interaction profile for the combination of retigabine (RTG) and oxcarbazepine (OXC) in both, the model of tonic-clonic seizures, the maximal electroshock (MES)-induced seizure model and chimney test (motor

Mirosław Zagaja, Barbara Miziak, Katarzyna Załuska, Paweł Marzęda, Bartłomiej Drop, Karolina Załuska-Patel, Grażyna Ossowska, Stanisław J. Czuczwar, Jarogniew J. Łuszczki

Journal of Epileptology, Volume 24 , ISSUE 2, 87–94

Case report | 11-March-2014

Successful treatment with adjunctive lacosamide in a patient with long term “drug resistant” focal epilepsy

Introduction. A significant number of patients suffering from epilepsy prove to be resistant to antiepileptic drugs (AEDs). Recent studies, however, suggest that 10–20% of seemingly drug resistant patients may still become seizure-free under the influence of subsequent dosage modifications. Case report. We report on a young man with cryptogenic focal epilepsy. He had his first seizure at the age of fifteen. His seizure frequency was decreased during the following 11 years. However

Walter Fröscher, Alois Rauber

Journal of Epileptology, Volume 22 , ISSUE 1, 51–55

Original Paper | 02-April-2015

The ILAE definition of drug resistant epilepsy and its clinical applicability compared with “older” established definitions

course of disease were extracted from patients' charts. Drug resistant epilepsy was classified according to four definitions and the time until fulfillment of criteria compared. Results. Mean time to fulfillment of criteria of drug resistant epilepsy ranged from 11.8 (standard deviation (SD) 9.8) to 15.6 years (SD 11.3). Time to drug resistance was significantly longer applying the only definition, requiring failure of three antiepileptic drugs (AEDs) (Canada definition), whereas time to

Alexandra Rohracher, Judith Dobesberger, Claudia A. Granbichler, Julia Höfler, Giorgi Kuchukhidze, Martin Ortler, Iris Unterberger, Gerald Walser, Aljoscha Thomschewski, Eugen Trinka

Journal of Epileptology, Volume 23 , ISSUE 1, 39–44

Case report | 05-June-2017

The diagnostic dilemma of non-convulsive status epilepticus in sporadic Creutzfeldt-Jakob disease

lateralized epileptiform discharges and NCSE was considered. Discussion. The presented case illustrates the dilemma in the differential diagnosis of sCJD and (symptomatic) NCSE in the light of the recently published new Salzburg consensus criteria and unified EEG terminology. Concerning these criteria, the patient showed after an initial generalized seizure and substantial clinical improvement after administration of antiepileptic drugs, persisting epileptic discharges and only subtle clinical ictal

Matthias Wittstock, Uwe Walter, Daniela Schirrmeister, Kyrylo Kurtieiev, Jan Klinke, Annette Grossmann, Johannes Rösche

Journal of Epileptology, Volume 25 , ISSUE 1-2, 53–58

Review Paper | 30-September-2016

The epileptic multifactorial patient’s burden. Review of the topic

. Generalized tonic-clonic seizures and refractory epilepsy are the most important factors burdening PWE’s, resulting in increased injuries and mortality, including Sudden Unexpected Death in Epilepsy (SUDEP). The need of chronic intake of antiepileptic drugs (AEDs) and of epilepsy surgery are also important with regards to potential for side effects, drug interactions, and different surgery risks. PWE harbour more medical and psychiatric comorbidities than the general population and results in a

José Pimentel

Journal of Epileptology, Volume 24 , ISSUE 2, 167–172

case-report | 21-November-2019

Glucose transporter type 1 deficiency syndrome (GLUT1-DS) – delayed diagnosis and treatment. A case report

administered 300 mg per day. The second and the last epileptic seizure was observed when she was six. She had been taking different antiepileptic drugs for the next sixteen years, because of sudden involuntary movements and sudden collapses which were diagnosed as epileptic seizures. In spite of many treatment modifications no clinical effect was noted. In the following years, the incidence of muscle fatigability, balance disturbances and anxiety lasting up to one hour, were often observed. The patient was

Piotr Bogucki, Ewa Nagańska, Marta Jurek, Dorota Hoffman-Zacharska, Anna Kutkowska-Kaźmierczak, Ewa Obersztyn, Urszula Fiszer

Journal of Epileptology, Volume 27 , 49–54

Review Paper | 30-November-2015

The role of cannabinoids and endocannabinoid system in the treatment of epilepsy

Introduction. The treatment of epilepsy is still a major challenge. Despite the introduction of many new antiepileptic drugs, approximately 30% of patients still remain drug resistant. In the absence of a satisfactory therapy outcome, which is sometimes associated with numerous side effects, there is a need for new and effective drugs with low toxicity. Cannabinoids have been shown in preliminary animal model studies and in studies of patients with epilepsy to have antiepileptic activity. Aim

Monika Pędracka, Jacek Gawłowicz

Journal of Epileptology, Volume 23 , ISSUE 2, 131–138

Review Paper | 19-January-2015

Neurostimulation, neuromodulation, and the treatment of epilepsies

magnetic stimulation (rTMS). Are these devices and techniques simply another treatment option that can be offered to patients with epilepsy or do they offer specific advantages when compared to the standard antiepileptic drugs (AEDs)? Aim. The aim of this review is to present the neurostimulation and neuromodulation devices and techniques that are now in use, or at least available for testing and to discuss the science behind them, their applications, efficacy, potential risks vs. benefits and, above

Lauren B. Bolden, Sandipan Pati, Jerzy P. Szaflarski

Journal of Epileptology, Volume 23 , ISSUE 1, 45–59

Review Paper | 07-April-2017

Genetic epilepsies. remarks on the proposed “organization of the Epilepsies”

include into genetic testing genes responsible for the side effects of AEDs. In addition, for some epilepsy phenotypes it has became possible to predict the most efficacious antiepileptic drugs for patients based on their genetic makeup. Thus, the development of individualized medicine is expected to greatly improve the management of epilepsy patients.

Heinz Gregor Wieser

Journal of Epileptology, Volume 22 , ISSUE 1, 11–23

Original Paper | 15-January-2018

Adenosine receptor agonists differentially affect the anticonvulsant action of carbamazepine and valproate against maximal electroshock test-induced seizures in mice

Background. Adenosine is regarded as an endogenous anticonvulsant and its agonists have been proved to affect the anticonvulsant activity of a number of antiepileptic drugs (AEDs) in animal models of seizures. Aim. To evaluate effects of adenosine agonists on carbamazepine (CBZ) and valproate (VPA) in mouse model of generalized tonic-clonic convulsions. Methods. The following adenosine receptor agonists were used: A 1 – cyclohexyladenosine, A2A – CGS 21 680, A3 – N6-benzyl

Mirosław Jasiński, Magdalena Chrościńska-Krawczyk, Stanisław J. Czuczwar

Journal of Epileptology, Volume 25 , ISSUE 1-2, 21–29

Original Paper | 03-April-2013

Neurobiological and clinical predictors of remission and antiepileptic treatment efficacy in partial epilepsies

were the worst combinations for the remission length and TLE • Fe • Lh • LF for the seizures reduction. Conclusions. The current study revealed the significance of combinations of some neurobiological and clinical variables in prediction of therapeutic remission and percent of seizures reduction irrespective of used antiepileptic drugs. These results may be used so as to aid patient selection before drug treatment in order to form the homogenous groups of persons.

Vladimir V. Kalinin, Anna A. Zemlyanaya, Elena V. Zheleznova, Lyudmila V. Sokolova

Journal of Epileptology, Volume 21 , ISSUE 1, 15–25

No Record Found..
Page Actions